Healthcare

  • AMSTERDAM WINS EMA PRIZE

    After more than 18 months of speculation, and the toss of a coin, we now know that the new host city for the European Medicines Agency (EMA) will be Amsterdam. In this short piece, we take the temperature of what this means for European citizens – and consider how high fevers can be avoided and…

  • EMA Race to the Finish

    This Brexit sweepstake ensures a hardy field of expectant contenders for one of Europe’s prized agencies. It remains a hard bet to place. If we assume good old politics will work its magic, the best team will not necessarily win. As we near the home stretch, will it be the seasoned work horse dominating the…

  • The FTI Consulting Brexit Healthcare Checklist

    Love it or hate it, there’s no way to avoid Brexit – and with the vote to decide the new location of the European Medicines Agency (EMA) around the corner, there will be significant challenges ahead for business, patient welfare and the broader healthcare sector in Europe. Are you ready for the big Brexit EMA…

  • PLACE YOUR BETS: FTI CONSULTING’S EMA RELOCATION GAME

    The EU vote on 20 November will decide the new location of the European Medicines Agency (EMA), one of the big Brexit prizes.  London will be a hard act to follow with none of the contenders having a perfect submission.  The six formal selection criteria need to be balanced against the reality of the need…

  • Life Sciences and Brexit – Intensive Care Needed?

    On 12 July 2017, the Healthcare and Life Sciences team of FTI Consulting’s Brussels office hosted an event entitled, “Brexit and Life Sciences: Intensive Care Needed?”, bringing together experts from the UK and Brussels to discuss the impact of Brexit on the healthcare sector and what it means for businesses on both sides of the…

  • Brexit & health: patience needed

    Discussing Brexit and its impact on the healthcare sector is a risky exercise, especially in the current rather blurred context. The UK Prime Minister, Theresa May, already under fire for failing to grasp the scale of the challenge facing the National Health Service (NHS), recently scrapped a high-level task force working on the issue. If…

  • mHealth’s time is now!

    “It’s time to seize the potential of mHealth”. This was the clear message of yesterday’s hearing on mHealth in the European Parliament. Commissioner Andriukaitis, Members of the European Parliament Peterle and Boni and participants all agreed that mHealth, and in particular health apps, have the power to transform the relationship between patients and doctors. Speakers…

  • UN Panel on Access to Medicines: What’s the impact on the pharmaceutical market?

    Following several months of intense discussion and negotiations, the High-Level Panel on Access to Medicines has published its report today. The 15 members of the panel, representing a wide range of experts and stakeholders in the health innovation area, have not found consensus on remedies to change the current IP system for medicines, but agreed…

  • ROBOTICS AND HEALTHCARE: Is the EU rising to the Opportunities and Threats?

    Technology is rapidly transforming the healthcare sector as we know it. While it is generally accepted that eHealth and mHealth can improve citizens’ possibility to monitor and evaluate their health, there is less knowledge about the wide range of uses of robotics in healthcare  – from  service robots in hospitals who deliver bed-linen and retrieve…

  • Brexit’s Impact on Healthcare and Life Sciences

    Health and life sciences are heavily regulated sectors, which directly employ a significant proportion of the workforce across health and care delivery, pharmaceuticals, research and development, education, animal health and the many other issues covered by the sector. The sector drives a significant percentage of trade inside and outside the EU market and healthcare consumes,…

Back to top